Patents by Inventor Martina Delbeck

Martina Delbeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240000767
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo [1,2-a]pyrimidine and substituted imidazo [1,2-a]pyridine derivatives of formula (II) and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: July 5, 2021
    Publication date: January 4, 2024
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20230115270
    Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 13, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Lisa DIETZ, Magdalena PLATZK, Daniel MEIBOM, Philipp BUCHGRABER, Niels LINDNER, Eva Maria BECKER-PELSTER, Carsten SCHMECK
  • Publication number: 20220259228
    Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1- and/or TASK-3-blocking properties.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 18, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael Hahn, Thomas Müller, Klemens Lustig, Johanna Anlahr, Udo Albus, Doris Gehring, Björn Rosenstein, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter
  • Publication number: 20220218695
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular diazabicyclically substituted imidazo [1,2-a]pyrimidine derivatives and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220218700
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular aryl piperazines of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220218677
    Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220016113
    Abstract: (alpha-2C) antagonists, in particular substituted piperidinyl-pyrimidinyl-tetra hydrochinolines and piperidinyl-pyridinyl-tetrahydrochinolines of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring. Formula (I) in which X is a group (A) or (B).
    Type: Application
    Filed: November 13, 2019
    Publication date: January 20, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220017540
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 20, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN
  • Patent number: 11208422
    Abstract: The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: December 28, 2021
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Klemens Lustig, Johanna Anlahr, Karl Collins, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, Björn Rosenstein, Hongkai Dang, Dehe Duan, Jianfei Yang, Denghui Chen
  • Publication number: 20210338662
    Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular aryl piperazines of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: September 19, 2019
    Publication date: November 4, 2021
    Applicant: Bayer Aktiengeselischaft
    Inventors: Martina DELBECK, Michael HAHN
  • Patent number: 11098063
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: August 24, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Klemens Lustig, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, Björn Rosenstein
  • Publication number: 20210024545
    Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1-and/or TASK-3-blocking properties.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 28, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Johanna ANLAHR, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER
  • Patent number: 10759794
    Abstract: The present application relates to novel 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: September 1, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Heinrich Meier, Klemens Lustig, Johanna Mosig, Luisella Toschi, Udo Albus, Doris Gehring, Björn Rosenstein
  • Publication number: 20200140461
    Abstract: The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.
    Type: Application
    Filed: June 7, 2018
    Publication date: May 7, 2020
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Johanna ANLAHR, Karl COLLINS, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN, Hongkai DANG, Dehe DUAN, Jianfei YANG, Denghui CHEN
  • Publication number: 20200109155
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 9, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN
  • Publication number: 20200093737
    Abstract: The invention relates to new pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and the use of same to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.
    Type: Application
    Filed: December 13, 2017
    Publication date: March 26, 2020
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Johanna ANLAHR, Moritz BECK-BROICHSITTER, Janine NICOLAI, Martina DELBECK, Michael HAHN, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN
  • Publication number: 20200085734
    Abstract: The invention relates to new pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and the use of same to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Application
    Filed: December 13, 2017
    Publication date: March 19, 2020
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Johanna ANLAHR, Moritz BECK-BROICHSITTER, Janine NICOLAI, Martina DELBECK, Michael HAHN, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN
  • Publication number: 20200016159
    Abstract: The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives having cyclic substituents in the 3 position, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 16, 2020
    Inventors: Michael HAERTER, Dirk KOSEMUND, Yolanda CANCHO GRANDE, Martina DELBECK, Bernd KALTHOF, Klemens LUSTIG, Frank SUESSMEIER
  • Patent number: 10479765
    Abstract: The present application relates to novel substituted N,2-diarylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and/or inflammatory disorders.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 19, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Beck, Tobias Thaler, Raimund Kast, Daniel Meibom, Mark Meininghaus, Carsten Terjung, Martina Delbeck, Klemens Lustig, Uwe Muenster, Britta Olenik
  • Patent number: 10428083
    Abstract: The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: October 1, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Michael Härter, Dirk Kosemund, Martina Delbeck, Bernd Kalthof, Pierre Wasnaire, Frank Süβmeier, Klemens Lustig